Biomarker‐based precision dose finding for immunotherapy combined with radiotherapy
Biometrical Journal · 2023-10 · 65 (7)
DOI: 10.1002/bimj.202200246 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biometrical Journal, online erschienen am 22.05.2023. Verfasst von Li-Hsiang Lin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Statistics, Louisiana State University, Baton Rouge, Louisiana, USA. Hauptthemen laut MEDLINE: Immunotherapy, Biometry, Precision Medicine, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: NIH HHS, American Cancer Society, Louisiana Board of Regents.
Abstract (Originalsprache)
Recent success of sequential administration of immunotherapy following radiotherapy (RT), often referred to as immunoRT, has sparked the urgent need for novel clinical trial designs to accommodate the unique features of immunoRT. For this purpose, we propose a Bayesian phase I/II design for immunotherapy administered after standard‐dose RT to identify the optimal dose that is personalized for each patient according to his/her measurements of PD‐L1 expression at baseline and post‐RT. We model the immune response, toxicity, and efficacy as functions of dose and patient's baseline and post‐RT PD‐L1 expression profile. We quantify the desirability of the dose using a utility function and propose a two‐stage dose‐finding algorithm to find the personalized optimal dose. Simulation studies show that our proposed design has good operating characteristics, with a high probability of identifying the personalized optimal dose.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Statistics, Louisiana State University, Baton Rouge, Louisiana, USA.
- Department of Biostatistics and Health Data Science, School of Medicine, Indiana University, Indianapolis, Indiana, USA.
- Department of Physics and Astronomy, Louisiana State University, Baton Rouge, Louisiana, USA.
- Department of Radiation Oncology, Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, USA.
ORCID-Profile: Beibei Guo
Förderung
- NIH HHS
- American Cancer Society
- Louisiana Board of Regents
- National Institutes of Health
Zitieren
APA
Lin, L. H., Han, Y., Zhang, R., & Guo, B. (2023). Biomarker‐based precision dose finding for immunotherapy combined with radiotherapy. Biometrical Journal, 65(7). https://doi.org/10.1002/bimj.202200246
Vancouver
Lin LH, Han Y, Zhang R, Guo B. Biomarker‐based precision dose finding for immunotherapy combined with radiotherapy. Biometrical Journal. 2023;65(7). doi:10.1002/bimj.202200246
BibTeX
@article{Lin2023,
author = {Lin, Li-Hsiang and Han, Yan and Zhang, Rui and Guo, Beibei},
title = {Biomarker‐based precision dose finding for immunotherapy combined with radiotherapy},
journal = {Biometrical Journal},
year = {2023},
volume = {65},
number = {7},
doi = {10.1002/bimj.202200246}
}
EUVIMED